e-learning
resources
Milan 2017
Monday, 11.09.2017
Update and new perspectives in Airway Diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients.
E. Khokhlovich (Cambridge, United States of America)
Source:
International Congress 2017 – Update and new perspectives in Airway Diseases
Session:
Update and new perspectives in Airway Diseases
Session type:
Oral Presentation
Number:
2897
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Khokhlovich (Cambridge, United States of America). Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients.. 2897
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Immunological mechanisms of intravenous roncoleucin (IL-2) clinical effects in asthmatic patients
Source: Eur Respir J 2002; 20: Suppl. 38, 512s
Year: 2002
Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019
Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy.
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough
Year: 2019
Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma
Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases
Year: 2007
Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma.
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO
Source: Virtual Congress 2021 – COVID-19 acute respiratory distress syndrome
Year: 2021
Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018
Late Breaking Abstract - Responder phenotyping using functional respiratory imaging (FRI) in IPF patients treated with anti-CGTG monoclonal antibody FG3019
Source: International Congress 2017 – Late-breaking findings in pulmonary diseases
Year: 2017
Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs
Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Year: 2020
Effects of anti-IL-1α, anti-IL-1β, anti-IL-18 and anti-IL-1RI antibodies on combined smoke and virus-induced airway inflammation in mice
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
Late Breaking Abstract - Compare outcomes between COPD patients treated with tiotropium/olodaterol (TIO/OLO) and umeclidium/vilanterol (UMEC/VI)
Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity
Year: 2020
Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED).
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies
Source: International Congress 2017 – Update and new perspectives in Airway Diseases
Year: 2017
Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept